Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Alyftrek (triple combination medicine ...
Many investors view the healthcare sector as a safe haven when the stock market is turbulent. Here are three no-brainer ...
Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily ...
UK MHRA approves Vertex’s Alyftrek, a once-daily next-in-class CFTR modulator to treat cystic fibrosis: London Monday, March 10, 2025, 10:00 Hrs [IST] Vertex Pharmaceuticals, a ...
What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...
The Nasdaq Composite Index ( ^IXIC -4.00%) is now squarely in correction territory. But stock market corrections have one key ...
Zacks Investment Research on MSN3d
Company News for Mar 11, 2025Shares of Vertex Pharmaceuticals Incorporated VRTX rose 2.4% on its cystic fibrosis drug Alyftrek getting approval in the United Kingdom. Shares of Tesla, Inc. TSLA plummeted 15.4% on the broad-based ...
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback